Results 151 to 160 of about 3,759,163 (248)

Lipid Mediators as Therapeutic Targets in Prostate Cancer. [PDF]

Cancers (Basel)
Balijepalli P, Meier KE.
europepmc   +1 more source

Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity

Advanced Science, EarlyView.
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang, Xiaowei Cai, Xiaoyan Zhong, Tian Qiu, Qinwei Lu, Jiahao Qin, Fei Gong, Yecheng Huang, Chenyu Jiang, Youdong Chen, Yuan Cheng, Liang Cheng   +11 more
wiley   +1 more source

Human Papillomavirus and Prostate Cancer: A Controversial Association. [PDF]

Pathogens
Sá S, Sousa M, Pereira AC, Baylina P, Cerqueira F.   +4 more
europepmc   +1 more source

Loss of CYLD on Chromosome 16q Impairs Homologous Recombination and Genomic Stability Through TIRR Degradation

Advanced Science, EarlyView.
Chromosome 16q loss drives genomic instability through disruption of the CYLD–TIRR–53BP1 axis. CYLD preserves homologous recombination by stabilizing TIRR and limiting 53BP1 accumulation at DNA double‐strand breaks. CYLD deficiency redirects repair toward error‐prone non‐homologous end joining, promotes mutational burden and homologous recombination ...
Mingming Lu, Jialu Kang, Qi Ye, Zixi Wang, Lei Li, Yuzeshi Lei, Leihong Ye, Tianjie Liu, Bin Wang, Tao Liu, Shan Xu, Ke Wang, Yong Zhang, Jian Ma, Lei Li   +14 more
wiley   +1 more source

Dietary inflammatory index and incident prostate cancer. [PDF]

Front Oncol
Li S, Chen Y, Zhou L, Wu T, Xu J, Yin M, Long H, Cao L.   +7 more
europepmc   +1 more source

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

Advanced Science, EarlyView.
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu, Wanying Xiang, Xinyue Wang, Yue Pan, Jing Gao, Jiezhen Yang, Yufei Wang, Zhipu Zhu, Man Tong, Lei Jin, Yan Ye   +10 more
wiley   +1 more source

Evaluation of FGD3 Expression in Advanced Prostate Cancer. [PDF]

Biomedicines
Malinowski B, Antosik P, Settaf-Cherif L, Grzanka D, Wiciński M.   +4 more
europepmc   +1 more source

GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27‐mediated ACLY Ubiquitination and Lipid Metabolism

Advanced Science, EarlyView.
GSTM4 enhances the interaction between ACLY and the E3 ubiquitin ligase TRIM27, thereby increasing K48‐linked ubiquitination at the K554 site of ACLY and promoting its degradation. Consequently, GSTM4 regulates lipid synthesis, as well as the proliferation and metastasis of PCa cells, by modulating ACLY stability.
Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng   +11 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

Advanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai, Xin Mei Zhang, Jing Cheng Zhang, Xu Ting Deng, Qiao Liu, Mustafa Hussein Ali, Fang Zhou Yin, Wu Yin   +7 more
wiley   +1 more source

ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer. [PDF]

Mol Cancer Res
Lorenzin F, Fracassi G, Vannuccini F, Ismail M, Ciani Y, Bevilacqua R, Gasperini P, Carbone FG, Cinalli S, Grist E, Devlies W, Giesen A, Van Goubergen J, Claessens F, Joniau S, Davicioni E, Barbareschi M, Rickman DS, Lunardi A, Attard G, Zoubeidi A, Demichelis F.   +21 more
europepmc   +1 more source